JLR Commentaries

Subscribe to collection
FilterHide Filter
  • Commentary
    Open Access

    Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?

    Journal of Lipid Research
    Vol. 56Issue 11p2045–2047Published online: September 16, 2015
    • Philip J. Barter
    • Fatiha Tabet
    • Kerry-Anne Rye
    Cited in Scopus: 3
      Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) and cholesteryl ester transfer protein (CETP) are both under current investigation as agents with the potential to reduce atherosclerotic cardiovascular disease (ASCVD) risk. Inhibitors of PCSK9 reduce the concentration of LDL cholesterol by more than 60%, while inhibitors of CETP reduce LDL cholesterol by up to 45% and increase HDL cholesterol by up to 180%.

    ASBMB  ASBMB  ASBMB  ASBMB

    ISSN 0022-2275
    We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
    Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


    RELX